乙型肝炎病毒前S1抗原与HBV血清标志物之间关系

目的探讨乙型肝炎病毒（HBV）前S1抗原（Pre—S1Ag）与HBV血清标志物（乙肝两对半）之间的关系,以评价其在乙肝诊疗中的作用。方法用ELISA法对512例HBsAg阳性标本进行Pre—S1Ag和HBV血清标志物的检测。结果在512例HBsAg阳性血清中,Pre—SlAg的阳性率为64．06％。Pre—slag与HBeAg具有较高的一致性,两者相符率为86．63％。结论作为反映HBV感染和复制的指标,Pre—S1Ag较HBeAg更敏感。     

前S1抗原—乙型肝炎病毒的传染性标志

通过临床和流行病学研究探讨前Ｓ１抗原作为乙型肝炎病毒（ＨＢＶ）一个传染性指标的意义。采取整群抽样和随机抽样方法收集血清１４４９份。ＨＢＶ—ＤＮＡ检测采用核酸斑点杂交法和ＰＣＲ法，其余指标测定采用ＥＬＩＳＡ法。结果显示，前Ｓ１抗原与ＨＢｅＡｇ同时在乙型肝炎患者血清中消失，它只能在ＨＢＶ—ＤＮＡ阳性血清中检出；前Ｓ１抗原阳性传播ＨＢＶ的危险性高于前Ｓ１抗原阴性的乙型肝炎患者和无症状ＨＢｓＡｇ携带者，其家庭成员感染ＨＢＶ的危险性也比较高。提示，前Ｓ１抗原为一个反映ＨＢＶ复制和传染性的指标。     

乙肝病毒DNA与前S1抗原在产前检查中的意义

目的:探讨乙肝病毒DNA(HBV DNA)和前S1抗原(Pre-S1 Ag)在产前检查中的意义。方法:从产前检查孕产妇标本中筛选出乙肝表面抗原阳性[HBsAg(+)]标本417例,乙肝病毒血清标志物(HBV-M)全阴性标本50例为对照,分别采用时间分辨荧光免疫分析法(TRFIA)检测HBV-M,荧光定量聚合酶链反应(FQ-PCR)检测HBV DNA和酶联免疫吸附法(ELISA)检测Pre-S1 Ag,对结果进行对比分析。结果:417例HBsAg(+)孕产妇中,HBV DNA与Pre-S1 Ag总阳性率比较,差异无统计学意义(P>0.05);HBV DNA与Pre-S1 Ag阳性率均高于HBeAg(-)组(P<0.05)。在185例HBV DNA(+)患者中有61例Pre-S1 Ag为阴性,232例HBV DNA(-)患者中有45例Pre-S1 Ag为阳性。50例血清标志物全阴性标本的HBV DNA与Pre-S1 Ag均为阴性。结论:在产前检查中增加HBV DNA与Pre-S1 Ag检测是对乙肝血清标志物的良好补充,联合检测有助于准确判断孕产妇体内是否存在乙肝病毒复制,以便临床及时采取阻断措施,减少病毒母婴传播。     

HBsAg无症状携带者乙型肝炎病毒核心基因启动子突变的研究

目的了解HBsAg无症状携带者乙型肝炎病毒(HBV)核心基因启动子双突变(nt1762 A→T,nt1764 G→A)发生情况及其与基因型、病毒量和HBeAg的关系。方法 HBsAg无症状携带者从隆安研究队列中选择,用套式聚合酶链反应(nested PCR)对研究对象血清HBV核心基因启动子、S基因扩增、序列分析及基因分型,用HBV引物和双标记的TaqMan探针扩增和定量病毒DNA。结果观察开始时核心基因启动子为野毒株的109例观察对象,3年后双突变平均年发生率为2.8%;观察开始时已发生nt1762或nt1764点突变的59例对象,3年后另一个位点也发生突变的平均年发生率为6.8%,两率差异有统计学意义(χ2=5.109 0,P<0.05)。nt1762 A→T突变组HBeAg阳性率(45.5%,10/22)与nt1764 G→A突变组HBeAg阳性率(10.8%,4/37)差异有统计学意义(χ2=9.149,P<0.05)。20例基因型B未发生双突变,重组基因型年双突变率为4.8%(2/14),基因型C年突变率为3.1%(7/75),各基因型间突变率差异无统计学意义(P>0.05)。5例双突变发生后HBeAg仍然阳性者病毒量有下降趋势,而另5例突变发生后HBeAg阴性者其病毒量有升有降。结论 HBV核心基因启动子双突变年发生率较高,这两个位点中的任何一个发生突变是双突变的过渡形式,双突变与基因型无关,nt1764 G→A突变与HBeAg阴性有关。     

Subgenotype D5, BCP and MHR mutations in hepatic complications among hepatitis B virus infected patients from Orissa,India

The study was undertaken to investigate the clinical implications of hepatitis B virus (HBV) genotypes, basal core promoter (BCP), precore (PC) and surface gene mutations in HBV infected patients from Orissa, southeastern India. HBV infections were identified by serology testing and HBV DNA amplification by polymerase chain reaction among the 152 patients. After sequencing, surface gene mutation were studied by sequence analysis as well as by using BLOSUM scores and BCP mutations were studied only by sequence analysis. A high proportion of HBV/D5 (66.0%) was found among the study samples having significant relation with liver cirrhosis (LC) and hepatocellular carcinoma (HCC) patients (p < 0.05). The BCP mutation, TA (81.4%) and C1753/TA (75.0%) was found in significant proportion (p < 0.05) among HCC cases and in fact a gradual increase in these mutations were noted between inactive carriers (IC) to HCC group and also showed higher viral load. An increasing trend of major hydrophilic region (MHR) mutations in S gene was also observed from IC (56.0%) to chronic liver disease (CLD) (60.4%) to LC (72.4%) to HCC (95.0%) patients. In conclusion, our study suggests that the predominant HBV subgenotype HBV/D5 with high viral load and BCP mutations (double and triple) and high mutations in MHR region was significantly associated with advanced liver disease (LC and HCC) and might act as predictor of severe hepatic complications.     

Genotype determination in Moroccan hepatitis B chronic carriers

BACKGROUND: In Morocco, chronic liver disease related to hepatitis B virus (HBV) is a public health burden. Treatment of chronic hepatitis B is often complicated by the appearance of escape mutants after treatment with nucleoside analogs, especially with genotypes responsible for the more severe form of the disease. OBJECTIVES: In the present study we investigate the prevalence of the different HBV genotypes in Morocco since no previous careful study has been attempted. METHODS: Epidemiological data from 91 chronically infected patients (45 women and 46 men) were collected prospectively. Sera were tested for anti-HBc IgG, HBeAg, anti-HBe antibody and liver enzymes. Restriction Fragment Length Polymorphism (RFLP) analysis was confirmed by subsequent sequencing of the pre-S and S region of the viral genome in order to determine which HBV genotypes were prevalent among Moroccan patients. RESULTS: The mean age was 41+/-12.4 years. Ten patients (11%) were positive for hepatitis B e antigen (HBeAg) and 81 (89%) were positive for anti-HBe antibodies. By the RLFP method, genotype D, pattern D2, was found in the 77 cases where HBV was successfully amplified. Phylogenetic analysis based on pre-S/S sequences revealed that genotype D in Morocco differed from others D strains subgenotypes (D1, D2, D3 and D4). In addition, the pre-core mutant defined as HBeAg-negative/anti-HBe-positive and HBV DNA positive was detected in 86% of cases. CONCLUSIONS: Our results clearly show that genotype D and pre-core mutant are highly prevalent in Morocco.     

前S1抗原、HBV DNA及HBeAg在乙型肝炎病毒检测中的临床意义

目的 了解乙型肝炎患者前S1抗原(Pre-S1)、HBV DNA及HBeAg的相关性,并评价它们在诊断HBV复制中的临床意义.方法 应用ELISA、荧光定量PCR法(FQ-PCR)对198例乙型肝炎患者进行Pre-S1、HBV DNA及HBV血清标志物五项(两对半)检测.结果 198例乙型肝炎患者中Pre-S1阳性107例(54.0%),HBV DNA阳性111例(56.1%),HBeAg阳性90例(45.5%),三者同时阳性72例(36.4%),Pre-S1与HBV DNA阳性率比较,差异无统计学意义(P>0.05).在90例HBeAg阳性样本中,Pre-S1阳性72例(80.0%),HBVDNA阳性74例(82.2%),三者具有较高的符合率.在108例HBeAg阴性样本中,Pre-S1阳性35例(32.4%),HBV DNA阳性37例(34.2%),Pre-S1与HBV DNA检出率比较,两者高度一致(χ2=0.08,P>0.05).结论 Pre-S1与HBV DNA能敏感反映HBV复制的情况,尤其可以协助诊断HBeAg阴性的乙型肝炎患者是否有HBV复制,对于判断患者的病情及指导治疗具有重要的临床意义.     

HBV genotypes prevalence, precore and basal core mutants in Morocco

The study of hepatitis B virus (HBV) genomic heterogeneity has become a major issue in investigations aimed at understanding the relationship between HBV mutants and the wide spectrum of clinical and pathological conditions associated with HBV infection. The objective of the current study was to find out the pattern of HBV genotypes circulating in Morocco and to investigate the precore (PC) and basal core promoter (BCP) mutants' status in Moroccan chronic hepatitis B patients. Viral genotypes were determined in 221 chronic carriers using INNO-LiPA HBV assay and hemi-nested PCR. Phylogenetic analysis was performed in 70 samples, and multiplex PCR method was used to confirm some genotyping results. PC and CP mutants were determined using Inno-Lipa. All isolates were successfully genotyped. The genotype distribution was D in 90.45% of cases, A (5.9%), E (1 case), and mixed genotypes (5 A/D and 2 D/F) in 3.17% patients. HBV carried in the HBV/D samples could be assigned to D7 (63.3%), D1 (32.7%) and 2% of strains to each D4 and D5, all HBV/A belonged to A2 subgenotype and HBV/E strain could not be sub-genotyped. In 70 studied strains, HBV mutants were detected in 88.6% of cases; PC mutants were detected in (40%) of patients and 21.5% present a mixture of wild type and G1896A mutation. BCP mutants were observed in 65.7% of cases, 22.9% were found to have the T1762/1764A double mutation, 18.6% had A1762/1764T mutation and 22.9% of patients showed the A1762T/G1764A double mutation with either A1762T/G1764T mutation. Co-infection by PC and BCP mutants was detected in 52.9% of cases. Movement from place to place most likely shapes the observed genotype distribution and consequent prevalence of genotypes other than A2 or D7 in this population. High circulation of PC and BCP mutants is common in chronic hepatitis B infection in Morocco.     

乙型肝炎病毒基因型和前C及基本核心启动子突变与乙型肝炎疫苗阻断母婴传播的关系

目的探讨乙型肝炎（乙肝）病毒（HBV）基因型和前C及基本核心启动子（BCP）突变与乙肝疫苗阻断母婴传播的关系。方法采集江苏省16对乙肝疫苗阻断失败的母婴血清样本32份,以及88对阻断成功的母婴血清样本176份。以型特异性引物PCR法检测16对乙肝疫苗阻断失败的母婴和88例阻断成功的母亲血清样本中HBV基因型,用PCR产物直接测序法检测HBV前C/ BCP突变,采用Clustal W 1．8软件进行序列分析。结果在16例阻断失败的母亲中,15例（93．8%）为HBeAg阳性,且均为C型（15/15,100%）;88例阻断成功的母亲中,51例（58．0%）为HBeAg阳性,其中C基因型占45．1%（23／51）。在HBeAg阳性母亲中,阻断失败组的C基因型检出率明显高于阻断成功组（X~2=14．3,P=0．003）。但在C基因型HBeAg阳性母亲中,阻断成功组与失败组的T1762/ A1764突变率差异无统计学意义（分别为13．3%和33．3%,P=0．4）,且均无A1896突变。结论感染HBV基因C型的母亲可能更易导致乙肝疫苗阻断失败,而前C/BCP基因突变与阻断母婴传播无关。     

Non-A hepatitis B virus genotypes in antenatal clinics, United Kingdom

In the United Kingdom, the National Screening Programme for identification of hepatitits B virus (HBV) infection in pregnant women uses HBV e antigen (HBeAg) and antibody to HBeAg (anti-HBe) as markers of infectivity to determine use of immunoglobulin for hepatitis B. Serum samples from 114 HBV-infected women were analyzed. Viral loads correlated with HBeAg/anti-HBe status and viral genotypes. Among 95 mothers whose serum contained anti-HBe, viral loads ranged between undetectable and 8.6 x 10(6) IU/mL (median 228 IU/mL). Ten (10.5%) of these mothers had plasma viral loads >10(4) IU/mL; 6 were infected with genotype E and one each with genotypes A, B, C, and D. All viruses had precore stop codon or basal core promoter mutations. Preponderance of genotypes other than A among antenatal mothers in the United Kingdom reflects increasing globalization and trends in immigration. HBeAg serostatus is no longer sufficiently accurate for inferring potential infectivity of pregnant HBV carriers.     

Calcium,Vitamin D,VDR Genotypes,and Epigenetic and Genetic Changes in Rectal Tumors

Calcium, vitamin D, exposure to sunshine, and vitamin D receptor (VDR) genotypes have been associated rectal cancer. We used data from 750 rectal tumors and 1,205 population-based controls examine associations with TP53, KRAS2, and CpG Island methylator phenotype (CIMP) markers. Rectal tumors were associated with high levels of calcium overall and with TP53 tumor mutations specifically (OR = 0.6, 95% CI = 0.42–0.84). High levels of sunshine exposure had a borderline protective effect for TP53 tumor mutations (OR = 0.78, 95% CI = 0.59–1.03). A mutation at codon 248 was significantly associated with dietary calcium intake (OR = 0.26, 95% CI = 0.09–0.77); having the Ff/ff genotypes of the FOK1 VDR polymorphism significantly increased the odds of a mutation at codon 245 (OR = 4.74, 95% CI = 1.05–21.39); high levels of dietary vitamin D (OR = 3.42, 95% CI = 1.15–10.17) and the Ff/ff genotypes of FOK1 (OR = 3.34, 95% CI = 1.11–10.02) and the GA/AA genotypes of the CDX2 VDR polymorphism (OR = 2.85, 95% CI = 1.23–6.58) increased the odds of a TP53 mutation at codon 273. These data support an association between calcium and rectal tumors overall as well as specifically with TP53 mutations. However, given the number of comparisons, findings need to be confirmed in other studies.     

乙型肝炎病毒前S1抗原的检测及其临床意义

目的探讨乙型肝炎病毒前S1抗原(PreS1Ag)在临床上的应用价值.方法采用酶联免疫吸附试验(ELISA)和聚合酶链反应(PCR)方法,对319例乙型病毒性肝炎(以下简称乙肝)患者和30例健康人分别检测HBV标志、PreS1抗原和乙肝病毒-脱氧核糖核酸(HBV-DNA).结果 319例乙型肝炎患者中PreS1抗原和HBV-DNA的检出率分别为51.7%和56.1%,两种方法符合率为92.1%;PreS1Ag在HBeAg阳性(1/3/5)和HBeAg阴性(1/4/5)中的阳性率分别为88.4%、31.1%,HBV-DNA在HBeAg阳性(1/3/5)和HBeAg阴性(1/4/5)中的阳性率分别为91.1%、34.1%,HBV-DNA检出率稍高于PreS1抗原的检出率,但两者的检出率差异无显著性(P＞0.05).结论乙肝病毒PreS1抗原与HBeAg阳性、HBV-DNA阳性呈高度相关,PreS1抗原可与HBeAg、HBV-DNA同时作为HBV存在复制和传染性的重要检测指标.     

HBV不同基因型致癌风险差异的系统综述和Meta分析

目的 探究不同基因型的HBV引发肝细胞癌(简称"肝癌")风险差异及其潜在机制.方法 通过检索数据库 PubMed、Web of Science、Embase、中国知网(China national knowledge infrastructure,CNKI)及万方数据获取相关数据,利用Meta分析的方法进行数据整合.从...     

贵州省乙型肝炎病毒前C区及基本核心启动子变异分布

目的调查贵州省乙型肝炎病毒(HBV)前C区A1896、基本核心启动子区(BCP) T1762/A1764变异分布。方法收集贵阳、遵义、凯里、都匀4地区不同民族无症状携带者(ASC)、慢性肝炎(CH)、肝炎肝硬化(LC)、肝细胞肝癌(HCC)患者血清482份,用测序及限制性片段长度多态性检测A1896、T1762/A1764变异,用S基因PCR-RFLP确定基因型。结果A1896、T1762/A1764变异检出率分别为23.03%和29.67%。汉族感染者A1896、T1762/A1764变异检出率为27.64%和36.04%,高于侗、苗、布依族感染者合并后的7.96%、8.85%(P<0.01)。A1896变异在B、C基因型中的分布为20.34%和27.13%(P>0.05),T1762/A1764变异为18.97%和46.28%(P<0.01)。A1896、T1762/A1764变异在HBeAg阴、阳性组间的分布差异有统计学意义(P值均<0.01)。从ASC到HCC组,A1896、T1762/A1764变异分布逐渐增高,LC、HCC组的检出率明显高于CH和ASC组(P值均<0.01)。A1896、T1762/A1764变异的分布:贵阳(分别为31.79%和41.06%)高于遵义(10.94%和14.06%)、都匀(8.64%和11.1I%)及凯里(2.86%和2.86%),但多因素logistic回归分析在控制了HBeAg、HBV基因型及临床类型影响后,在地区间分布差异无统计学意义。结论A1896、T1762/A1764变异在贵州省不同民族间分布有一定差异。C型感染者易发生T1762/A1764变异,两种变异均与疾病进展有关。     

HBV基因型与耐药变异的关系

目的探讨乙型肝炎病毒（HBV）基因型与核苷（酸）类似物耐药变异的关系。方法湖南省衡阳地区122例慢性乙型肝炎患者接受拉米夫定治疗（100mg／d）48-96周,发生耐药变异者改用阿德福韦酯治疗（10mg／d）96周。采用直接测序法进行HBV基因分型,同时检测拉米夫定、阿德福韦酯和恩替卡韦耐药变异位点。结果122例慢性乙型肝炎患者中,B基因型86例（70．49%）,C基因型24例（19．67％）,未分型12例（9．84％）。42例检出拉米夫定变异株,其中B基因型32例,C基因型10例,B、C基因型拉米夫定耐药变异率分别为37．21％（32／86）和41．67％（10／24）,差异无显著性（x^2=0．16,P=0．69）;42例经阿德福韦酯治疗48周和96周的变异发生率分别为0．00％（0／42）和2．38％（1／42）,B、C基因型阿德福韦酯耐药变异率分别为3．13％（1／32）和0．00％（0／10）。拉米夫定耐药变异类型主要为rtM204V＋rtL180M（35．71％）和rtM204I（38．10％）;B、C基因型比较,拉米夫定耐药变异类型差异无显著性（x^2=17．44,P=0．23）。结论湖南省衡阳地区HBV基因型以B型为主,C型次之;HBV基因型对拉米夫定耐药变异发生率及变异类型无明显影响。     

单纯乙型肝炎疫苗免疫后表面抗原携带者“a”决定簇基因变异的分子流行病学特征

目的　了解单纯乙型肝炎疫苗免疫失败后表面抗原 ( HBs Ag)携带者和未免疫携带者 HBs Ag基因变异的流行特点及乙型肝炎病毒 ( HBV)基因型和血清亚型的分布特点。　方法　应用直接测序和基因序列特异固相聚合酶链反应( SS- SPPCR)方法 ,分别检测 69例单纯乙型肝炎疫苗免疫后携带者和 83例未免疫携带者 ,乙型肝炎病毒 HBs Ag“a”决定簇氨基酸的变异及 HBV基因型和血清亚型的分布。　结果　 HBV基因型 B、C和 D均存在 ,其中 B和 C为优势基因型 ;血清亚型 adr、adw2、avr、ayw1、ayw2和 ayw3均存在 ,其中 adr和 adw2为优势血清亚型。直接测序检测的乙型肝炎疫苗免疫后携带者 HBs Ag“a”决定簇氨基酸变异率明显高于未免疫携带者对照 ,变异率分别为 3 1.9% ( 2 2 / 69)和 8.4 % ( 7/ 83 )。14 5、12 6和 13 3位是最常见的氨基酸变异点。应用更为敏感的 SS- SPPCR法分别检测 14 5和 12 6位氨基酸点突变的变异率 ,各组间差别不明显。经直接测序法检测 ,免疫后携带者基因变异危险度 ( OR)是未免疫携带者的 5 .1倍。按基因型和血清亚型分层分析 ,基因型 B和 adw2血清亚型携带者受免疫后出现基因变异的危险度明显高于未免疫携带者 ,分别为3 1.7和 2 8.9。　结论　接种乙型肝炎疫苗者可引起表面抗原基因的免疫逃避     

Molecular epidemiology of hepatitis B virus in Paraguay

Hepatitis B virus (HBV) infection is a leading cause of severe chronic liver disease worldwide. The HBV epidemiology in Latin American countries is complex and the data is still scanty and fragmentary. The aim of this study was to investigate the distribution of HBV genotypes in Paraguay and to estimate the viral population dynamic and spread pattern of the main phylogenetic group. To this end, partial and complete genome sequences were obtained from 60 blood donor candidates and analysed by phylogenetic and Bayesian phylodynamic approaches.The phylogenetic analysis based on sequences of partial Polymerase/Pre-S1 overlapping region showed a predominance of the Native American subgenotype F4 (81.7%), the presence of the European subgenotypes A2 (1.7%) and D3 (8.3%), the African subgenotype A1 (3, 5%) and the Asian subgenotypes B2 (1.7%) and C2 (1.7%). The distribution of HBV genotypes was in accordance with the ethnic composition of the population.The phylogeographic analysis of subgenotype F4 complete genomes suggests that this lineage emerged and spread in the last 300 years. Paraguay was the most probable location of the common ancestor. The lineage diverged into two main clades and spread to neighbor regions, mainly Bolivia and Northwest Argentina, and Buenos Aires. The phylogeny showed a scanty geographical structure and a complex migratory pattern.In conclusion, the HBV genotypes circulating in Paraguay reflect the ethnic origin of the population. The distribution of genotypes and the phylogeographic reconstruction showed the impact of both global and local migrations in shaping the HBV molecular epidemiology in the region.     

Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence,liver cirrhosis,and hepatocellular carcinoma

Human leukocyte antigen (HLA)-DQ genetic polymorphisms have been associated with chronic hepatitis B virus (HBV) outcomes. We aimed to determine impacts of HLA-DQ polymorphisms and their interactions with HBV mutations on the risks of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). rs2856718 (A > G) and rs9275319 (A > G) were genotyped in 1342 healthy controls, 327 HBV surface antigen (HBsAg) seroclearance subjects, 611 asymptomatic HBsAg carriers (ASCs), 1144 chronic hepatitis B (CHB) patients, 734 LC patients, and 1531 HCC patients using quantitative PCR. HBV mutations were detected by direct sequencing. Logistic regression analyses were utilized to assess the factors and/or multiplicative interactions significantly associated with liver diseases. rs9275319 variant genotypes were inversely associated with HBV persistence compared to HBV natural clearance subjects. rs2856718 variant genotypes significantly increased LC risk compared to ASCs plus CHB patients (GG vs. AA: odds ratio [OR], 1.52, 95% confidence interval [CI], 1.17–1.97 and AG + GG vs. AA: OR, 1.27; 95% CI, 1.04–1.54) and decreased HCC risk compared to HCC-free HBV-infected subjects (AG vs. AA: OR, 0.76; 95% CI, 0.65–0.89 and AG + GG vs. AA: OR, 0.78, 95% CI, 0.68–0.90). rs2856718 variant genotypes were significantly associated with an increased frequency of HBV A1726C mutation, a LC-risk, HCC-protective mutation, in genotype C. A rs9275319 variant genotype (GG) was significantly associated with an increased frequency of preS1 start codon mutation, an HCC-risk mutation, in genotype C. The interaction of rs2856718 AG + GG genotype with T1753V, a HCC-risk mutation, significantly reduced LC risk, with an OR of 0.26 (95% CI, 0.09–0.78); whereas the interaction of rs2856718 AG genotype with C1673T, a LC-risk mutation, significantly increased HCC risk, with an OR of 2.80 (95% CI, 1.02–7.66) in genotype C HBV-infected subjects. Conclusively, the HLA-DQ polymorphisms affect the risks of LC and HCC differently in chronic HBV-infected subjects, possibly via interacting with the HBV mutations.     

乙型肝炎病毒前S1抗原与其血清标志物及DNA的关系分析

目的 探讨HBV前S1抗原(Pre-S1)与HBV血清标志物(HBV-M)及HBV DNA的关系.方法 采用ELISA法检测880例乙型肝炎患者血清Pre-S1和HBV-M,采用荧光定量PCR法检测HBV DNA载量,并分析三者间的相关性.结果 在880例乙型肝炎患者中,前S1抗原和HBeAg的阳性率分别为56.25％...     

HBV基因型与慢性乙型肝炎疾病谱的关系

目的　探讨乙型肝炎病毒 (HBV)基因型与慢性乙型肝炎疾病谱相关性。方法　用S基因聚合酶链式反应 -限制片段长度多态性 (PCR -RFLP)的基因型分型方法对广东地区HBV感染者中无症状携带者 (AsC)组 80例和肝硬化组 (LC) 12 0例血清标本分型 ,比较两组基因型分布的异同。结果　基因型在AsC组分布 :B型 45 0 % ( 3 7/ 80 ) ;C型 3 3 75 % ( 2 6/ 80 ) ;D基因型 2 1 2 5 % ( 17/80 ) ;LC组HBV基因型分布B型 3 2 5 % ( 3 9/ 12 0 ) ;C型 65 8% ( 79/ 12 0 ) ;D基因型 1 6% ( 2 / 12 0 )。广州地区未发现A、E和F基因型 ,基因型在两组中的分布均与e抗原状态无显著性差异 (P >0 0 5 ) ;ASC与LC组两组间基因型的分布有显著性差异 ( χ2 =3 1 92 4,P=0 0 0 0 )。结论　可初步认为广东地区HBV感染者以B和C型为优势基因型 ,AsC组中以B型为优势基因型 ,感染HBVD基因型病情轻 ,感染HBVC基因型病情更易于加重。